ADHD pills lead to other drugs, hormone therapy guidelines have been updated and Novo Nordisk and Eli Lilly cut obesity drug prices. Read more in this week's WSJ Health newsletter:WSJ • 11/21/25
Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employersReuters • 11/21/25
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Nov 2025)24/7 Wall Street • 11/21/25
Focus: High-stakes Novo Nordisk Alzheimer's studies could yield answers on GLP-1 benefitReuters • 11/20/25
Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly?The Motley Fool • 11/20/25
Researchers move closer to matching patients with GLP-1 drug that works best for themReuters • 11/19/25
Why biotech and drug stocks are on the mend even though the rest of the market is hurtingMarket Watch • 11/18/25
Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle?The Motley Fool • 11/18/25
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?Zacks Investment Research • 11/17/25
Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It's a Worry for the Stocks.Barrons • 11/17/25